Nureca Quarterly Results for Trading Insights
Latest Quarter Net Profit
₹-6 Cr
QMar 2026
In Mar 2026, Nureca (NURECA) reported revenue ₹36 Cr and net profit ₹-6 Cr — revenue +5.9% YoY. Browse Nureca financial data for revenue, profit, balance sheet and cash flow data.
NURECA Quarterly Results — Revenue, Profit & EPS Highlights
Nureca latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore NURECA share price history to track price trends across different timeframes.
- Revenue of ₹36 Cr in Mar 2026 (-10.0% vs Sept 2025, +5.9% vs Mar 2025)
- Net Profit of ₹-6 Cr in Mar 2026 (-250.0% vs Sept 2025, -300.0% vs Mar 2025)
- EBITDA of ₹-5 Cr in Mar 2026 (-183.3% vs Sept 2025)
- Operating Margin of -16.0% in Mar 2026 (-25.0pp vs Sept 2025)
- Earnings Per Share of ₹-6.45 in Mar 2026 (-277.7% vs Sept 2025)
Nureca Quarterly Results — Revenue, EBITDA, Net Profit & EPS
NURECA quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 36 | 40 | 34 | 37 | 42 | -10.0% | 5.9% |
| Net Profit (₹ Cr) | -6 | 4 | 3 | 1 | 4 | - | - |
| EBITDA (₹ Cr) | -5 | 6 | 3 | 2 | 5 | - | - |
| EPS (₹) | -6.45 | 3.63 | 2.47 | 0.81 | 3.91 | - | - |
| Operating Margin (%) | -16.0% | 9.0% | 4.0% | -2.0% | 8.0% | - | - |
NURECA Share Price Trend — 1-Year Movement Across Quarterly Results
Nureca 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Nureca share price chart.
Revenue Trend (₹ Cr)
Jun 2025
37
Mar 2025
34
Sept 2025
40
Mar 2026
36
Net Profit Trend (₹ Cr)
Jun 2025
1
Mar 2025
3
Sept 2025
4
Mar 2026
-6
Operating Margin Trend (%)
Jun 2025
-2.0%
Mar 2025
4.0%
Sept 2025
9.0%
Mar 2026
-16.0%
NURECA vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Nureca latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹457,721.13 Cr | 1912.8 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 169.3 |
|
Divis Laboratories
Mar 2026 |
₹174,081.02 Cr | 6857.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 242.2 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹161,380.94 Cr | 4822.7 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 419.0 |
|
Cipla
Mar 2026 |
₹117,800.00 Cr | 1472.3 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 214.3 |
|
Zydus Life Science
Mar 2026 |
₹115,505.60 Cr | 1147.9 | 7,569 | 1,341 | +23.1% | +18.8% | 17.7% | 90.7 |
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores
All amounts in ₹ Crores